Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
Blog
Paper on Potential of Beta-Glucan Products to Prevent and Treat Non-Alcoholic Fatty Liver Disease
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
Value addition to Japanese technologies by GN Corp, featured in Government of Japan official website
GNC’s activities are introduced in the Japan Cabinet Office’s site ‘Invest Japan’
A study of Nichi Glucan on children with autism has been published in Research Features Magazine
This is the research on the potential of beta-glucan for autism
Rejuvenating human cartilage cells in the lab, proven by miRNA140 enhancement
A breakthrough achievement on miRNA140 is published in Medicine Innovates
GN Corp track record published in Bloomberg
An interview was published in a feature story in Bloomburg
Autism Sunday 2022: Commemoration and Panel discussion
GN Corporation participates in the “Autism Sunday” to be held on February 13, 2022
NCRM NICHE 2021 and Fujio Cup Quiz on stem cells to be held virtually on 17th October 2021
The NCRM NICHE 2021 is held virtually on 17 Oct 2021
Encouraging outcome of the clinical study on Beta Glucan for Covid-19 patients published
This is the study on Beta glucan food supplements potential in Covid-19 patients
Tackling long COVID-19, with safety proven Japanese Beta Glucans; The first clinical report in the world
Paper on potential of beta glucan products is pubrished